NCT00118157View on ClinicalTrials.gov

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

July 31, 2011

Study Completion Date

September 30, 2014

Conditions
Estrogen Receptor PositiveMale Breast CarcinomaProgesterone Receptor PositiveRecurrent Breast CarcinomaStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lapatinib Ditosylate

Given PO

DRUG

Tamoxifen Citrate

Given PO

Trial Locations (2)

48201

Harper University Hospital - DMC, Detroit

Wayne State University/Karmanos Cancer Institute, Detroit

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00118157 - Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen | Biotech Hunter | Biotech Hunter